Immunogenicity of varicella vaccine and immunologic predictors of response in a cohort of elderly nursing home residents

Journal of Infectious Diseases

Volumn 214, Issue 12, 2016, Pages 1905-1910

  Lelic, Alina ^a   Verschoor, Chris P ^a,b   Lau, Vivian W C ^a   Parsons, Robin ^a   Evelegh, Carole ^a   Bowdish, Dawn M ^a,c   Bramson, Jonathan L ^a   Loeb, Mark B ^a,c,d  

^a MCMASTER UNIVERSITY   (Canada)

^b Étude longitudinale canadienne sur le vieillissement éLCV   (Canada)

^c Institute of Infectious Diseases Research   (Canada)

^d MCMASTER UNIVERSITY   (Canada)

Author keywords

Immunogenicity; Nursing home; T cells; Vaccine; Varicella zoster

Indexed keywords

CELL MARKER; GAMMA INTERFERON; VARICELLA ZOSTER VACCINE; CHICKENPOX VACCINE;

ABSENCE OF SIDE EFFECTS; AGED; ARTICLE; CD4+ T LYMPHOCYTE; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOMEGALOVIRUS; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; FRAIL ELDERLY; HERPES ZOSTER; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOSENESCENCE; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; NONHUMAN; NURSING HOME PATIENT; PREDICTION; REGULATORY T LYMPHOCYTE; VACCINATION; VACCINE IMMUNOGENICITY; VARICELLA ZOSTER VIRUS; VERY ELDERLY; IMMUNOLOGY; MONONUCLEAR CELL; NURSING HOME; SECRETION (PROCESS);

AGED, 80 AND OVER; CHICKENPOX VACCINE; COHORT STUDIES; ENZYME-LINKED IMMUNOSPOT ASSAY; FEMALE; HUMANS; INTERFERON-GAMMA; LEUKOCYTES, MONONUCLEAR; MALE; NURSING HOMES;

EID: 85016044360     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jiw462     Document Type: Article

References (36)

1. Goldman GS, King PG. Review of the United States universal varicella vaccination program: Herpes zoster incidence rates, cost-effectiveness, and vaccine efficacy based primarily on the Antelope Valley Varicella Active Surveillance Project data. Vaccine 2013; 31:1680-94.
2. Shapiro M, Kvern B, Watson P, Guenther L, McElhaney J, McGeer A. Update on herpes zoster vaccination: a family practitioner's guide. Can Fam Physician Médecin Fam Can 2011; 57:1127-31.
3. Brisson M, Edmunds WJ, Law B, et al. Epidemiology of varicella zoster virus infection in Canada and the United Kingdom. Epidemiol Infect. 2001; 127:305-14.
4. O'Connor KM, Paauw DS. Herpes zoster. Med Clin North Am 2013; 97:503-22.
5. Kinchington PR, Leger AJS, Guedon J-MG, Hendricks RL. Herpes simplex virus and varicella zoster virus, the house guests who never leave. Herpesviridae 2012; 3:5.
6. Levin MJ, Smith JG, Kaufhold RM, et al. Decline in varicella-zoster virus (VZV)-specific cell-mediated immunity with increasing age and boosting with a highdose VZV vaccine. J Infect Dis 2003; 188:1336-44.
7. Levin MJ. Immune senescence and vaccines to prevent herpes zoster in older persons. Curr Opin Immunol 2012; 24:494-500.
8. Szucs TD, Kressig RW, Papageorgiou M, et al. Economic evaluation of a vaccine for the prevention of herpes zoster and post-herpetic neuralgia in older adults in Switzerland. Hum Vaccine 2011; 7:749-56.
9. Oxman MN, Levin MJ, Johnson GR, et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med 2005; 352:2271-84.
10. Schmader KE, Johnson GR, Saddier P, et al. Effect of a zoster vaccine on herpes zoster-related interference with functional status and health-related quality-of-life measures in older adults. J Am Geriatr Soc 2010; 58:1634-41.
11. Amanna IJ. Balancing the Efficacy and Safety of Vaccines in the Elderly. Open Longev Sci 2012; 6:64-72.
12. Steain M, Sutherland JP, Rodriguez M, Cunningham AL, Slobedman B, Abendroth A. Analysis of T cell responses during active varicella-zoster virus reactivation in human ganglia. J Virol 2014; 88:2704-16.
13. Johnstone J, Parsons R, Botelho F, et al. Immune biomarkers predictive of respiratory viral infection in elderly nursing home residents. PLoS One 2014; 9: e108481.
14. Verschoor CP, Loukov D, Naidoo A, et al. Circulating TNF and mitochondrial DNA are major determinants of neutrophil phenotype in the advanced-age, frail elderly. Mol Immunol 2015; 65:148-56.
15. Johnstone J, Millar J, Lelic A, et al. Immunosenescence in the nursing home elderly. BMC Geriatr 2014; 14:50.
16. Verschoor CP, Johnstone J, Millar J, et al. Blood CD33(+)HLA-DR(-) myeloid-derived suppressor cells are increased with age and a history of cancer. J Leukoc Biol 2013; 93:633-7.
17. Verschoor CP, Johnstone J, Millar J, et al. Alterations to the frequency and function of peripheral blood monocytes and associations with chronic disease in the advanced-age, frail elderly. PLoS One 2014; 9:e104522.
18. Wikby A, Nilsson B-O, Forsey R, et al. The immune risk phenotype is associated with IL-6 in the terminal decline stage: findings from the Swedish NONA immune longitudinal study of very late life functioning. Mech Ageing Dev 2006; 127:695-704.
19. Jagger A, Shimojima Y, Goronzy JJ, Weyand CM. Regulatory T cells and the immune aging process: a mini-review. Gerontology 2014; 60:130-7.
20. Haralambieva IH, Painter SD, Kennedy RB, et al. The impact of immunosenescence on humoral immune response variation after influenza A/H1N1 vaccination in older subjects. PLoS One 2015; 10:e0122282.
21. Drinka PJ. How should nursing homes use vaccine to prevent zoster? J Am Med Dir Assoc 2007; 8:419-20.
22. Ma L, White RR, Narayanan S, Schmader KE. Economic burden of herpes zoster among skilled nursing facility residents in the United States. J Am Med Dir Assoc. 2012; 13:54-9.
23. Rockwood K, Mogilner A, Mitnitski A. Changes with age in the distribution of a frailty index. Mech Ageing Dev 2004; 125:517-9.
24. Tabue-Teguo M, Kelaiditi E, Demougeot L, Dartigues J-F, Vellas B, Cesari M. Frailty Index and Mortality in Nursing Home Residents in France: Results From the INCUR Study. J Am Med Dir Assoc 2015; 16:603-6.
25. Disis ML, dela Rosa C, Goodell V, et al. Maximizing the retention of antigen specific lymphocyte function after cryopreservation. J Immunol Methods 2006; 308:13-8.
26. Smith JG, Liu X, Kaufhold RM, Clair J, Caulfield MJ. Development and Validation of a Gamma Interferon ELISPOT Assay for Quantitation of Cellular Immune Responses to Varicella-Zoster Virus. Clin Diagn Lab Immunol 2001; 8:871-9.
27. Levin MJ, Oxman MN, Zhang JH, et al. Varicella-zoster virus-specific immune responses in elderly recipients of a herpes zoster vaccine. J Infect Dis 2008; 197:825-35.
28. Williams RE, Sena AC, Moorman AC, et al. Hepatitis B vaccination of susceptible elderly residents of long term care facilities during a hepatitis B outbreak. Vaccine 2012; 30:3147-50.
29. Li X, Zhang JH, Betts RF, et al. Modeling the durability of ZOSTAVAX® vaccine efficacy in people ?60 years of age. Vaccine 2015; 33:1499-505.
30. Wing K, Sakaguchi S. Regulatory T cells exert checks and balances on self tolerance and autoimmunity. Nat Immunol 2010; 11:7-13.
31. Heit A, Gebhardt F, Lahl K, et al. Circumvention of regulatory CD4(+) T cell activity during cross-priming strongly enhances T cell-mediated immunity. Eur J Immunol 2008; 38:1585-97.
32. Richardson K, Weinberg A. Reduced immunogenicity of influenza vaccines in HIV-infected compared with uninfected pregnant women is associated with regulatory T cells. AIDS Lond Engl 2011; 25:595-602.
33. Frasca D, Diaz A, Romero M, Landin AM, Blomberg BB. Cytomegalovirus (CMV) seropositivity decreases B cell responses to the influenza vaccine. Vaccine 2015; 33:1433-9.
34. Derhovanessian E, Maier AB, Hähnel K, McElhaney JE, Slagboom EP, Pawelec G. Latent infection with cytomegalovirus is associated with poor memory CD4 responses to influenza A core proteins in the elderly. J Immunol 2014; 193:3624-31.
35. Wald A, Selke S, Magaret A, Boeckh M. Impact of human cytomegalovirus (CMV) infection on immune response to pandemic 2009 H1N1 influenza vaccine in healthy adults. J Med Virol 2013; 85:1557-60.
36. Lemmermann NAW, Böhm V, Holtappels R, Reddehase MJ. In vivo impact of cytomegalovirus evasion of CD8 T-cell immunity: facts and thoughts based on murine models. Virus Res 2011; 157:161-74.